About Us
We want to do more than just treat monogenic CNS disease. We want to eradicate it.
Integrity
We are thoughtful, transparent and strive to do what is right, always staying true to who we are and what we stand for.
Our Story
Taysha Gene Therapies is singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), in both rare and large patient populations. The team’s primary focus is advancing our lead clinical program in Rett syndrome, and our pipeline of CNS programs offers additional development opportunities.
Our leaders include pioneers in gene therapy and rare diseases, having been responsible for the discovery, development and commercialization of the first U.S. FDA approved gene therapy to treat a monogenic CNS disorder. This experience has led to strong relationships with key stakeholders that are imperative to future drug development.
Our team of experienced scientists, clinicians and patient advocates are driven to develop treatments that have the potential to dramatically improve the lives of patients and their families. This shared passion and drive is what makes us Taysha.
Our Mission
Our mission is to eradicate monogenic diseases of the central nervous system.
Our Defining Values
At our core, we embody shared values that represent our identity and guide our behaviors, decisions and actions. We believe living out these values will support our efforts to deliver transformative treatments to patients and families.
Accountability
We deliver on our commitments and hold ourselves responsible for our actions and decisions.
Teamwork
We work together and apply our collective knowledge and expertise to achieve breakthroughs in gene therapy.
Our Team
We’ve assembled the experts.
Our team is comprised of some of the most accomplished and knowledgeable gene therapy and CNS disease experts. Together – armed with our unrelenting, patient-first focus – we are working to bring new treatments to life.
Leadership Team
Board of Directors
Sean Nolan
Chief Executive Officer and Board Chairman
Sukumar Nagendran, M.D.
President and Head of Research and Development
Laura Sepp-Lorenzino, Ph.D.
Chief Scientific Officer, Intellia Therapeutics
Alison Long, M.D., Ph.D.
Chief Medical Officer, Flightpath Biosciences
Phillip Donenberg, CPA
Former Chief Financial Officer, AveXis
Sean Stalfort
President, PBM Capital
Independent Scientific Advisory Board
Chief Advisors
Berge Minassian, M.D.
Chief Medical Advisor
UT Southwestern Gene Therapy Program
Steven Gray, Ph.D.
Chief Scientific Advisor
UT Southwestern Gene Therapy Program
Sean Nolan
/in Board of Directors, Leadership TeamChief Executive Officer and Board Chairman
Sukumar Nagendran, M.D.
/in Board of Directors, Leadership TeamPresident and Head of Research and Development
Meredith Schultz, M.D., M.S.
/in Leadership TeamChief Medical Officer
Kamran Alam
/in Leadership TeamChief Financial Officer
Emily McGinnis
/in Leadership TeamChief Patient and External Affairs Officer, and Endpoint and Outcome Development Lead
Rumana Haque-Ahmed
/in Leadership TeamChief Regulatory Officer
Fred Porter, Ph.D.
/in Leadership TeamChief of Staff and Technical Operations Officer
Sean McAuliffe
/in Leadership TeamChief Business Officer
Tracy M. Porter, M.Ed., SPHR
/in Leadership TeamChief People Officer